You are here: Industry Insights > Phase III

News List

Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease americanpharmaceuticalreview
June 27, 2018
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced the initiation of two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD).
Phase III success for Janssen’s esketamine in treatment-resistant depression pharmatimes
June 21, 2018
Janssen has presented data from pivotal Phase III clinical studies backing use of esketamine spray in treatment-resistant depression.
Update on Phase III clinical trials of lanabecestat for Alzheimer's disease worldpharmanews
June 20, 2018
AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor
Merck announces findings from Phase III study of KEYTRUDA expressbpd
September 14, 2017
The findings include updated survival data showing a 19 per cent reduction in the risk of death over standard treatment in the intent-to-treat population
RedHill Biopharma announces successful Phase III pharmaasia
July 04, 2017
RedHill Biopharma announces successful Phase III top-line results with BEKINDA for Acute Gastroenteritis.

Previous page 1 2 Next page